Sangamo raises $65m as stock gains momentum
This article was originally published in Scrip
Executive Summary
Sangamo Biosciences is taking advantage of the recent upswing in the company's stock price to raise $65m to fund ongoing Phase II clinical trials for its HIV program and eventually move some of its early-stage assets into the clinic.